Journal
ONCOGENESIS
Volume 12, Issue 1, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41389-023-00493-z
Keywords
-
Categories
Ask authors/readers for more resources
Elevated expression of WDR4 in bladder cancer is associated with worse prognosis, as it promotes lymph node metastasis and proliferation of bladder cancer cells. WDR4 acts as an adaptor to bind DDX20 and Egr1, inhibiting Egr1-promoted transcriptional expression of ARRB2 and contributing to the progression of bladder cancer. WDR4 could be a potential therapeutic target for metastatic bladder cancer.
Lymph node (LN) metastasis is one of the key prognostic factors in bladder cancer, but its underlying mechanisms remain unclear. Here, we found that elevated expression of WD repeat domain 4 (WDR4) in bladder cancer correlated with worse prognosis. WDR4 can promote the LN metastasis and proliferation of bladder cancer cells. Mechanistic studies showed that WDR4 can promote the nuclear localization of DEAD-box helicase 20 (DDX20) and act as an adaptor to bind DDX20 and Early growth response 1 (Egr1), thereby inhibiting Egr1-promoted transcriptional expression of arrestin beta 2 (ARRB2) and ultimately contributing to the progression of bladder cancer. Immunohistochemical analysis confirmed that WDR4 expression is also an independent predictor of LN metastasis in bladder cancer. Our results reveal a novel mechanism of LN metastasis and progression in bladder cancer and identify WDR4 as a potential therapeutic target for metastatic bladder cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available